Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength

Osteoporosis International

Volumn 25, Issue 8, 2014, Pages 2097-2107

  Sinder, B P ^a,b   White, L E ^a   Salemi, J D ^a,b   Ominsky, M S ^c   Caird, M S ^a   Marini, J C ^d   Kozloff, K M ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c AMGEN INC   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Mouse model; Osteogenesis imperfecta; Osteoporosis; Sclerostin antibody

Indexed keywords

ANABOLIC AGENT; NEUTRALIZING ANTIBODY; OSTEOCALCIN; SCL AB VI; SCLEROSTIN; SCLEROSTIN ANTIBODY; UNCLASSIFIED DRUG; ACID PHOSPHATASE; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; ISOENZYME; SOST PROTEIN, HUMAN; TARTRATE-RESISTANT ACID PHOSPHATASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MASS; BONE STRENGTH; COL1A1 GENE; CONTROLLED STUDY; CORTICAL BONE; FEMALE; GENE; INFANT; MALE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOGENESIS IMPERFECTA; PRIORITY JOURNAL; TRABECULAR BONE; TREATMENT RESPONSE; ANIMAL; BLOOD; BODY MASS; BONE DENSITY; BONE DEVELOPMENT; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; FEMUR; GENETIC MARKER; IMMUNOLOGY; MECHANICAL STRESS; MUTANT MOUSE STRAIN; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

ACID PHOSPHATASE; ANABOLIC AGENTS; ANIMALS; ANTIBODIES, NEUTRALIZING; BODY MASS INDEX; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMUR; GENETIC MARKERS; ISOENZYMES; MALE; MICE, MUTANT STRAINS; OSTEOCALCIN; OSTEOGENESIS; OSTEOGENESIS IMPERFECTA; STRESS, MECHANICAL; X-RAY MICROTOMOGRAPHY;

EID: 84904444064     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-014-2737-y     Document Type: Article

References (33)

1. Forlino A, Cabral WA, Barnes AM, Marini JC (2011) New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol 7:540-557. doi:10.1038/nrendo.2011. 81
2. Paterson CR, McAllion S, Stellman JL (1984) Osteogenesis imperfecta after the menopause. N Engl J Med 310:1694-1696. doi:10.1056/NEJM198406283102602 (Pubitemid 14124590)
3. Chevrel G, Schott A-M, Fontanges E et al (2006) Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res 21:300-306. doi:10.1359/JBMR.051015 (Pubitemid 43265296)
4. Adami S, Gatti D, Colapietro F et al (2003) Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 18:126-130. doi:10.1359/jbmr.2003.18.1.126 (Pubitemid 36008347)
5. Shapiro JR, Thompson CB, Wu Y et al (2010) Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta. Calcif Tissue Int 87:120-129. doi:10.1007/s00223-010- 9383-y
6. Bradbury LA, Barlow S, Geoghegan F et al (2012) Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists. Osteoporos Int 23:285-294. doi:10.1007/s00198-011-1658-2
7. Gatti D, Rossini M, Viapiana O et al (2013) Teriparatide treatment in adult patients with osteogenesis imperfecta type I. Calcif Tissue Int 93:448-452. doi:10.1007/s00223-013-9770-2
8. Orwoll ES, Shapiro J, Veith S et al (2014) Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Invest 124:491-498. doi:10.1172/JCI71101
9. Poole KES, van Bezooijen RL, Loveridge N et al (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19:1842-1844. doi:10.1096/fj.05-4221fje (Pubitemid 41598769)
10. Li X, Zhang Y, Kang H et al (2005) Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883-19887. doi:10.1074/jbc.M413274200 (Pubitemid 41379516)
11. Leupin O, Piters E, Halleux C et al (2011) Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem 286:19489-19500. doi:10.1074/jbc.M110.190330
12. Padhi D, Jang G, Stouch B et al (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19-26. doi:10.1002/jbmr.173
13. Li X, Ominsky MS, Warmington KS et al (2009) Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24:578-588. doi:10.1359/jbmr.081206
14. Ominsky MS, Vlasseros F, Jolette J et al (2010) Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 25:948-959. doi:10.1002/jbmr.14
15. McClung MR, Grauer A, Boonen S et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412-420. doi:10.1056/NEJMoa1305224
16. Forlino A, Porter FD, Lee EJ et al (1999) Use of the Cre/lox recombination system to develop a non-lethal knock-in murine model for osteogenesis imperfecta with an α1(I) G349C substitution. J Biol Chem 274:37923-37931. doi:10.1074/jbc.274.53.37923 (Pubitemid 30026860)
17. Kozloff KM, Carden A, Bergwitz C et al (2004) Brittle IV mouse model for osteogenesis imperfecta IV demonstrates postpubertal adaptations to improve whole bone strength. J Bone Miner Res 19:614-622. doi:10.1359/JBMR.040111 (Pubitemid 41071222)
18. Uveges TE, Collin-Osdoby P, Cabral WA et al (2008) Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors. J Bone Miner Res 23:1983-1994. doi:10.1359/jbmr.080804
19. Uveges TE, Kozloff KM, Ty JM et al (2009) Alendronate treatment of the Brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation. J Bone Miner Res 24:849-859. doi:10.1359/jbmr.081238
20. Sinder BP, Eddy MM, Ominsky MS et al (2013) Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta. J Bone Miner Res 28:73-80. doi:10.1002/jbmr.1717
21. Meganck JA, Kozloff KM, Thornton MM et al (2009) Beam hardening artifacts in micro-computed tomography scanning can be reduced by X-ray beam filtration and the resulting images can be used to accurately measure BMD. Bone 45:1104-1116. doi:10.1016/j.bone.2009.07.078
22. Otsu N (1979) A threshold selection method from gray-level histograms. IEEE Trans Syst Man Cybern 9:62-66
23. Hildebrand T, Rüegsegger P (1997) A new method for the model-independent assessment of thickness in three-dimensional images. J Microsc 185:67-75. doi:10.1046/j.1365-2818.1997.1340694.x (Pubitemid 27060526)
24. Reeves GM, McCreadie BR, Chen S et al (2007) Quantitative trait loci modulate vertebral morphology and mechanical properties in a population of 18-month-old genetically heterogeneous mice. Bone 40:433-443. doi:10.1016/j.bone.2006.08.018 (Pubitemid 46054549)
25. Parfitt AM, Drezner MK, Glorieux FH et al (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610. doi:10.1002/jbmr.5650020617
26. Sinder B, Salemi J, Caird M, et al (2013) Sclerostin antibody increases cortical bone thickness in a rapidly growing Brtl/+ model of OI by inducing bone formation on quiescent or resorbing surfaces. J Bone Miner Res 28 (Suppl 1)
27. Bivi N, Condon KW, Allen MR et al (2012) Cell autonomous requirement of connexin 43 for osteocyte survival: consequences for endocortical resorption and periosteal bone formation. J Bone Miner Res 27:374-389. doi:10.1002/jbmr.548
28. Sinder B, White L, Caird M, et al (2012) Sclerostin antibody improves bone mass and mechanical properties in Brtl/+ model of osteogenesis imperfecta when administered during growth. J Bone Miner Res 27 (Suppl 1)
29. Tian X, Setterberg RB, Li X et al (2010) Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone 47:529-533. doi:10.1016/j.bone.2010.05. 032
30. Kishi T, Hagino H, Kishimoto H, Nagashima H (1998) Bone responses at various skeletal sites to human parathyroid hormone in ovariectomized rats: effects of long-term administration, withdrawal, and readministration. Bone 22:515-522. doi:10.1016/S8756-3282(98)00045-3 (Pubitemid 28226866)
31. Li M, Liang H, Shen Y, Wronski TJ (1999) Parathyroid hormone stimulates cancellous bone formation at skeletal sites regardless of marrow composition in ovariectomized rats. Bone 24:95-100 (Pubitemid 29070799)
32. Chow JW, Fox S, Jagger CJ, Chambers TJ (1998) Role for parathyroid hormone in mechanical responsiveness of rat bone. Am J Physiol 274:E146-E154
33. Vanlenthe G, Voide R, Boyd S, Muller R (2008) Tissue modulus calculated from beam theory is biased by bone size and geometry: implications for the use of three-point bending tests to determine bone tissue modulus. Bone 43:717-723. doi:10.1016/j.bone.2008.06.008